HC Wainwright Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price cut by stock analysts at HC Wainwright from $455.00 to $250.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright‘s price objective would indicate a potential upside of 56.51% from the stock’s previous close.

A number of other analysts have also recently commented on the stock. Zacks Research cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 23rd. Jefferies Financial Group upped their price target on shares of Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a “hold” rating in a research report on Tuesday, September 8th. Needham & Company LLC decreased their price target on shares of Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating on the stock in a research note on Thursday, October 29th. JPMorgan Chase & Co. lowered their price objective on Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating on the stock in a report on Wednesday, September 30th. Finally, UBS Group lowered their price objective on Alnylam Pharmaceuticals from $550.00 to $329.00 and set a “buy” rating on the stock in a report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.57.

Check Out Our Latest Stock Report on Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $159.73 on Tuesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. The firm has a fifty day moving average of $217.12 and a 200 day moving average of $275.05. The firm has a market cap of $21.39 billion, a PE ratio of 8.29 and a beta of 0.42. Alnylam Pharmaceuticals has a one year low of $149.18 and a one year high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.66 by $14.60. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the firm posted $2.90 earnings per share. As a group, research analysts predict that Alnylam Pharmaceuticals will post 6.85 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the sale, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its position in Alnylam Pharmaceuticals by 9.0% in the second quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock worth $635,296,000 after acquiring an additional 174,482 shares during the period. Dodge & Cox increased its stake in Alnylam Pharmaceuticals by 2.6% during the third quarter. Dodge & Cox now owns 2,006,492 shares of the biopharmaceutical company’s stock worth $495,082,000 after acquiring an additional 51,099 shares during the last quarter. Legal & General Group Plc acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth $278,321,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Alnylam Pharmaceuticals by 7.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 727,848 shares of the biopharmaceutical company’s stock worth $219,104,000 after acquiring an additional 50,329 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at $148,128,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

(Get Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Read More

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.